{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:58Z","timestamp":1787839198407,"version":"build-2784847793"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The level of measurable residual disease (MRD) before and after transplantation is related to inferior transplant outcomes, and post-hematopoietic stem cell transplantation measurable residual disease (post-HSCT MRD) has higher prognostic value in determining risk than pre-hematopoietic stem cell transplantation measurable residual disease (pre-HSCT MRD). However, only a few work has been devoted to the risk factors for positive post-HSCT MRD in patients with acute lymphoblastic leukemia (ALL). This study evaluated the risk factors for post-HSCT MRD positivity in patients with ALL who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 1683 ALL patients from Peking University People\u2019s Hospital between January 2009 and December 2019 were enrolled to evaluate the cumulative incidence of post-HSCT MRD. Cox proportional hazard regression models were built for time-to-event outcomes. Multivariable analysis was performed to determine independent influencing factors from the univariable analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Both in total patients and in T-cell ALL or B-cell ALL, pediatric or adult, human leukocyte antigen-matched sibling donor transplantation or haploidentical SCT subgroups, positive pre-HSCT MRD was a risk factor for post-HSCT MRD positivity (<jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;0.001 for all). Disease status (complete remission 1 [CR1] <jats:italic toggle=\"yes\">vs<\/jats:italic>. \u2265CR2) was also a risk factor for post-HSCT MRD positivity in all patients and in the B cell-ALL, pediatric, or haploidentical SCT subgroups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.027; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.003; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.035; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.003, respectively). A risk score for post-HSCT MRD positivity was developed using the variables pre-HSCT MRD and disease status. The cumulative incidence of post-HSCT MRD positivity was 12.3%, 25.1%, and 38.8% for subjects with scores of 0, 1, and 2\u20133, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;0.001). Multivariable analysis confirmed the association of the risk score with the cumulative incidence of post-HSCT MRD positivity and relapse as well as leukemia-free survival and overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our results indicated that positive pre-MRD and disease status were two independent risk factors for post-HSCT MRD positivity in patients with ALL who underwent allo-HSCT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003150","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:06:53Z","timestamp":1720519613000},"page":"1084-1093","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"138","author":[{"given":"Yuewen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomei","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People\u2019s Hospital and National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"},{"name":"Department of Hematology, Peking University People\u2019s Hospital and National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China"},{"name":"Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","article-title":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: Current advances, challenges, and future directions","volume":"9","author":"Chang","year":"2022","journal-title":"Lancet Haematol"},{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(22)00036-9","article-title":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: Results from the prospective, single-arm evaluation of the UKALL14 trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/CM9.0000000000001999","article-title":"Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission","volume":"135","author":"Zhang","year":"2022","journal-title":"Chin Med J"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1097\/CM9.0000000000002764","article-title":"Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"136","author":"Zhao","year":"2023","journal-title":"Chin Med J"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","article-title":"Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: A biologically phase iii randomized study","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1078-0432.CCR-21-2675","article-title":"20-year steady increase in survival of adult patients with relapsed Philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation","volume":"28","author":"Bazarbachi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14737140.2020.1766973","article-title":"Measurable residual disease of acute lymphoblastic leukemia in allograft settings: How to evaluate and intervene","volume":"20","author":"Sun","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.22.01760","article-title":"Childhood acute lymphoblastic leukemia: Results of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-Munster 2009 trial","volume":"41","author":"Campbell","year":"2023","journal-title":"J Clin Oncol"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrov\u00e1","year":"2022","journal-title":"Blood Adv"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/CM9.0000000000001852","article-title":"Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph- high-risk B-cell acute lymphoblastic leukemia","volume":"135","author":"Fan","year":"2022","journal-title":"Chin Med J"},{"key":"R14-20250512","first-page":"1855","article-title":"More than two courses of pre-transplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: A multicenter study","volume":"136","author":"Liu","year":"2023","journal-title":"Chin Med J"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cyto.b.21840","article-title":"The quantification of minimal residual disease pre- and post-unmanipulated haploidentical allograft by multiparameter flow cytometry in pediatric acute lymphoblastic leukemia","volume":"98","author":"Wang","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: Pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.26634","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10(-4) and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/s41375-020-01090-4","article-title":"A new pre-emptive TKIs strategy for preventing relapse based on BCR\/ABL monitoring for Ph+ALL undergoing allo-HCT: A prospective clinical cohort study","volume":"35","author":"Liu","year":"2021","journal-title":"Leukemia"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41375-021-01351-w","article-title":"Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Zhao","year":"2022","journal-title":"Leukemia"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.bbmt.2017.04.023","article-title":"IFN-alpha is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: Results of a registry study","volume":"23","author":"Mo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.12639","article-title":"Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: Is there any room for intervention?","volume":"164","author":"Balduzzi","year":"2014","journal-title":"Br J Haematol"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","article-title":"Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: A phase 3 genetically randomized study","volume":"13","author":"Chang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajh.25417","article-title":"Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts","volume":"94","author":"Zhao","year":"2019","journal-title":"Am J Hematol"},{"key":"R26-20250512","first-page":"267","article-title":"Chinese consensus on minimal residual disease detection and interpretation of patients with acute lymphoblastic leukemia (2023) (in Chinese)","volume":"44","year":"2023","journal-title":"Chinese Journal of Hematology"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3324\/haematol.2022.281177","article-title":"Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia","volume":"108","author":"Masic","year":"2023","journal-title":"Haematologica"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"key":"R31-20250512","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"R32-20250512","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.jtct.2022.03.017","article-title":"Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission","volume":"28","author":"Kaito","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","article-title":"Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"14","author":"Nagler","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/petr.12704","article-title":"Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia","volume":"20","author":"Xu","year":"2016","journal-title":"Pediatr Transplant"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.bbmt.2012.07.011","article-title":"Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia","volume":"18","author":"Bakr","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"R37-20250512","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"R38-20250512","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtct.2022.05.010","article-title":"Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia in the modern era","volume":"28","author":"Liang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R39-20250512","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","article-title":"Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"6","author":"Wieduwilt","year":"2022","journal-title":"Blood Adv"},{"key":"R40-20250512","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CM9.0000000000002945","article-title":"Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy","volume":"137","author":"Lin","year":"2023","journal-title":"Chin Med J"},{"key":"R41-20250512","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/bloodadvances.2018025726","article-title":"Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia","volume":"3","author":"Keating","year":"2019","journal-title":"Blood Adv"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:00:34Z","timestamp":1747022434000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003150","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}